Status:
COMPLETED
Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
50+ years
Phase:
PHASE1
Brief Summary
The purpose of the study is to characterise the absorption, distribution, metabolism and excretion (ADME) of a single oral dose of \[14C\]AZD9668.
Eligibility Criteria
Inclusion
- Provision of signed, written and dated informed consent prior to any study specific procedure
- Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg
Exclusion
- Exposed to radiation levels above background of \>5 mSv in the last year, \>10 mSv over the last 5 years or a cumulative total of \>1 mSv per year of life
- History or presence of any clinically significant disease or disorder in the opinion of the investigator
- Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs or ECG at baseline in the opinion of the investigator
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT01147549
Start Date
June 1 2010
End Date
July 1 2010
Last Update
December 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London, United Kingdom